Welcome to the first ProrateNIH newsletter. We will strive to keep all of you throughout the USA updated on a regular basis as to our efforts to obtain equitable National Institutes of Health (NIH) research distributions for the sixteen diseases that kill more Americans than AIDS and to eliminate the outrageous NIH allocation bias that now favors AIDS. If you aren’t presently a member, we’d be honored to have you join us at Join.

ProrateNIH at HFI Conference  

ProrateNIH was well represented at the recent Hepatitis Foundation International conference in La Mirada, CA, as Dr. Darling and Mr. Rick Smith attended and passed out approximately 500 flyers that illustrated the NIH bias in favor of AIDS over all other diseases that kill more Americans. Dr. Darling and Rick had the opportunity to answer many questions that arose as most people are not aware that AIDS killed only 256 in California (2000) and 14,800 in the entire country (1999). AIDS deaths continue to plummet while deaths from The 16 and other diseases either stay at their present rate or increase. The HFI conference, under the direction of CEO Thelma King, was a resounding success with many wonderful speakers educating the attendees on HCV. As a result of Dr. Darling and Rick's attendance, dozens of new members have joined ProrateNIH and have expressed their desire for change in the allocation priorities at the NIH.

Diseases with Low Mortality Rates

Although ProrateNIH's goal is the proration of NIH research monies based on a disease's mortality rate, that proration will have a floor under which funding shall not fall so illnesses that don't have high morbidity rates, but do cause great suffering, such as multiple sclerosis, lupus, progeria, spinal cord injury, sickle cell disease, fibromyalgia, etc., will also receive increased research funds with proration.

ProrateNIH Board of Directors 

We are proud to announce two esteemed members from the Loma Linda University Medical Center, Loma Linda, CA, have joined our Board of Directors: Dr. Waldo Concepcion, Director of Liver, Kidney and Pancreas transplantation, and Director of the Medial Center Transplantation Institute Education and Research Fund; and Dr. Donald Hillebrand, Hepatologist, Chief of Hepatology, and Medical Director, Liver Transplantation.

The FAIR Foundation
Dr. Richard Darling, DDS, Founder
P.O. Box 11991
Palm Desert, CA 92211
Ph: 760-200-2766
E-mail: FAIR@dc.rr.com

Prorate Mission Statement: NIH research allocations shall be allocated based on a disease's mortality rate. If you have a disease that is killing the most Americans, it shall receive the largest allocation, if it is killing the second largest number, it shall receive the second largest research funding and so on. Secondary factors insure diseases with lower mortality rates but that produce great suffering shall also receive increased research funding.